These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37363820)

  • 1. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
    Uson PLS; Bearss J; Babiker HM; Borad M
    Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
    Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
    Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE
    Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
    Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
    Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
    Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
    Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
    Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
    Vogel A; Sahai V; Hollebecque A; Vaccaro GM; Melisi D; Al Rajabi RM; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Lihou CF; Zhen H; Veronese ML; Abou-Alfa GK
    ESMO Open; 2024 Jun; 9(6):103488. PubMed ID: 38838500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
    Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
    J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
    Lindley A; Prager G; Bitzer M; Burn TC; Lihou CF; Croft E
    Cancer Res Treat; 2024 Jul; 56(3):847-855. PubMed ID: 38351684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
    Uson Junior PLS; Borad MJ
    Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicogenomic Analysis of
    Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
    Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
    Rengan AK; Denlinger CS
    J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
    Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
    Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemigatinib: First Approval.
    Hoy SM
    Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
    J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
    Merz V; Zecchetto C; Melisi D
    Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.